50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
OTCMKTS:BPMUF

Basilea Pharmaceutica - BPMUF Stock Forecast, Price & News

$41.00
0.00 (0.00%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$41.00
$41.00
50-Day Range
$41.00
$41.00
52-Week Range
$41.00
$41.00
Volume
N/A
Average Volume
0 shs
Market Capitalization
$485.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$84.00

Basilea Pharmaceutica MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.9% Upside
$84.00 Price Target
Short Interest
Bearish
3.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.47) to $0.56 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

BPMUF stock logo

About Basilea Pharmaceutica (OTCMKTS:BPMUF) Stock

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Stock News Headlines

Basilea reports on portfolio progress made in 2021
Basilea Pharma: FDA Allows To Proceed With Phase 1 Study For BAL0891
See More Headlines
Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Company Calendar

Today
9/28/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BPMUF
CIK
N/A
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$84.00
High Stock Price Forecast
$84.00
Low Stock Price Forecast
$84.00
Forecasted Upside/Downside
+104.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$162.08 million
Book Value
($5.97) per share

Miscellaneous

Free Float
N/A
Market Cap
$485.85 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Mr. David Veitch (Age 57)
    Chief Exec. Officer
    Comp: $1.15M
  • Mr. Adesh Kaul (Age 48)
    Chief Financial Officer
  • Dr. Gerrit Hauck Ph.D. (Age 58)
    Chief Technology Officer
  • Dr. Laurenz Kellenberger Ph.D. (Age 55)
    Chief Scientific Officer
  • Dr. Marc Engelhardt M.D. (Age 58)
    Chief Medical Officer
  • Dr. Peer Nils Schroder
    Head of Corp. Communications & Investor Relations
  • Mr. Damian Heller (Age 56)
    Gen. Counsel & Corp. Sec.
  • Ms. Ursula Eberhardt (Age 60)
    Head of Global HR
  • Mr. Lutz Wevelsiep
    Head of Regulatory Affairs
  • Mr. Dietrich Stüber
    Head of Internal Services













BPMUF Stock - Frequently Asked Questions

Should I buy or sell Basilea Pharmaceutica stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMUF shares.
View BPMUF analyst ratings
or view top-rated stocks.

What is Basilea Pharmaceutica's stock price forecast for 2022?

1 brokers have issued 1-year price targets for Basilea Pharmaceutica's shares. Their BPMUF share price forecasts range from $84.00 to $84.00. On average, they expect the company's stock price to reach $84.00 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for BPMUF
or view top-rated stocks among Wall Street analysts.

How have BPMUF shares performed in 2022?

Basilea Pharmaceutica's stock was trading at $41.00 at the beginning of 2022. Since then, BPMUF stock has increased by 0.0% and is now trading at $41.00.
View the best growth stocks for 2022 here
.

What is Basilea Pharmaceutica's stock symbol?

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Basilea Pharmaceutica's stock price today?

One share of BPMUF stock can currently be purchased for approximately $41.00.

How much money does Basilea Pharmaceutica make?

Basilea Pharmaceutica (OTCMKTS:BPMUF) has a market capitalization of $485.85 million and generates $162.08 million in revenue each year.

How many employees does Basilea Pharmaceutica have?

The company employs 154 workers across the globe.

How can I contact Basilea Pharmaceutica?

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The official website for the company is www.basilea.com. The company can be reached via phone at (161) 606-1111, via email at investor_relations@basilea.com, or via fax at 41-61-606-1112.

This page (OTCMKTS:BPMUF) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.